Cui et al. (114) demonstrated that diosgenin can stimulate anti-tumor immunity in NSCLC by decreasing IL-10 secretion from TAM in the TME, modulating STAT3 and JNK signaling pathways, and facilitating the polarization of M2-TAM to M1-TAM. This evidence concerns the gene STAT3 and neoplasm.